Liberty Dialysis-Hawaii Ala Moana is a medicare approved dialysis facility center in Honolulu, Hawaii and it has 3 dialysis stations. It is located in Honolulu county at 500 Ala Moana Blvd, Suite 7302, Honolulu, HI, 96813. You can reach out to the office of Liberty Dialysis-Hawaii Ala Moana at (808) 566-6388. This dialysis clinic is managed and/or owned by Fresenius Medical Care. Liberty Dialysis-Hawaii Ala Moana has the following ownership type - Profit. It was first certified by medicare in March, 2018. The medicare id for this facility is 122532 and it accepts patients under medicare ESRD program.
| Name | Liberty Dialysis-Hawaii Ala Moana |
|---|---|
| Location | 500 Ala Moana Blvd, Suite 7302, Honolulu, Hawaii |
| No. of Dialysis Stations | 3 |
| Medicare ID | 122532 |
| Managed By | Fresenius Medical Care |
| Ownership Type | Profit |
| Late Shifts | No |
| 500 Ala Moana Blvd, Suite 7302, Honolulu, Hawaii, 96813 | |
| (808) 566-6388 | |
| Not Available |
News Archive
In spring 2005 a large European research and training network was established to investigate the causes and implications of poor sleep from a medical as well as from a social point of view. This EU-financed sleep research project, "The biomedical and sociological effects of sleep restriction", is coordinated by Dr. Tarja Porkka-Heiskanen (Stenberg) MD, PhD, at the University of Helsinki, Institute of Biomedicine.
Doing away with the regulations, which it has deemed are "excessively burdensome," would save an estimated $676 million a year, according to the administration. In other news, The Medicare NewsGroup examines the population of people with a permanent disability who also qualify for Medicare.
GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody against phosphorylated Histone H3.
APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States. APP will begin shipping Meropenem for Injection the week of February 13, 2012 with Imipenem and Cilastatin for Injection scheduled to ship in the next three to five weeks.
› Verified 4 days ago
| NPI Number | 1265800965 |
| Organization Name | Fresenius Medical Care Ala Moana |
| Doing Business As | Liberty Dialysis - Hawaii, Llc |
| Address | 500 Ala Moana Blvd Honolulu, Hawaii, 96813 |
| Phone Number | (808) 537-1100 |
News Archive
In spring 2005 a large European research and training network was established to investigate the causes and implications of poor sleep from a medical as well as from a social point of view. This EU-financed sleep research project, "The biomedical and sociological effects of sleep restriction", is coordinated by Dr. Tarja Porkka-Heiskanen (Stenberg) MD, PhD, at the University of Helsinki, Institute of Biomedicine.
Doing away with the regulations, which it has deemed are "excessively burdensome," would save an estimated $676 million a year, according to the administration. In other news, The Medicare NewsGroup examines the population of people with a permanent disability who also qualify for Medicare.
GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody against phosphorylated Histone H3.
APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States. APP will begin shipping Meropenem for Injection the week of February 13, 2012 with Imipenem and Cilastatin for Injection scheduled to ship in the next three to five weeks.
› Verified 4 days ago
| NPI Number | 1346528494 |
| Organization Name | Liberty Dialysis - Hawaii Home Dialysis Program |
| Doing Business As | Liberty Dialysis - Hawaii, Llc |
| Address | 500 Ala Moana Blvd Honolulu, Hawaii, 96813 |
| Phone Number | (808) 585-4600 |
News Archive
In spring 2005 a large European research and training network was established to investigate the causes and implications of poor sleep from a medical as well as from a social point of view. This EU-financed sleep research project, "The biomedical and sociological effects of sleep restriction", is coordinated by Dr. Tarja Porkka-Heiskanen (Stenberg) MD, PhD, at the University of Helsinki, Institute of Biomedicine.
Doing away with the regulations, which it has deemed are "excessively burdensome," would save an estimated $676 million a year, according to the administration. In other news, The Medicare NewsGroup examines the population of people with a permanent disability who also qualify for Medicare.
GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody against phosphorylated Histone H3.
APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States. APP will begin shipping Meropenem for Injection the week of February 13, 2012 with Imipenem and Cilastatin for Injection scheduled to ship in the next three to five weeks.
› Verified 4 days ago
| NPI Number | 1467971465 |
| Organization Name | Liberty Dialysis - Hawaii Ala Moana |
| Doing Business As | Liberty Dialysis - Hawaii Llc |
| Address | 500 Ala Moana Blvd Ste 7302 Honolulu, Hawaii, 96813 |
| Phone Number | (808) 245-6032 |
News Archive
In spring 2005 a large European research and training network was established to investigate the causes and implications of poor sleep from a medical as well as from a social point of view. This EU-financed sleep research project, "The biomedical and sociological effects of sleep restriction", is coordinated by Dr. Tarja Porkka-Heiskanen (Stenberg) MD, PhD, at the University of Helsinki, Institute of Biomedicine.
Doing away with the regulations, which it has deemed are "excessively burdensome," would save an estimated $676 million a year, according to the administration. In other news, The Medicare NewsGroup examines the population of people with a permanent disability who also qualify for Medicare.
GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody against phosphorylated Histone H3.
APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States. APP will begin shipping Meropenem for Injection the week of February 13, 2012 with Imipenem and Cilastatin for Injection scheduled to ship in the next three to five weeks.
› Verified 4 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
DSI Honolulu Dialysis Center Location: 226 N. Kuakini St, Honolulu, Hawaii, 96817 Phone: (808) 545-3933 |
DSI Aloha Dialysis Center Location: 1520 Liliha Street, Suite 101, Honolulu, Hawaii, 96817 Phone: (808) 531-1748 |
Siemsen Dialysis Facility Location: 2226 Liliha Street Suite 226, Honolulu, Hawaii, 96817 Phone: (808) 585-4660 |
DSI Kapahulu Dialysis Center Location: 750 Palani Avenue, Honolulu, Hawaii, 96816 Phone: (808) 732-7702 |
News Archive
In spring 2005 a large European research and training network was established to investigate the causes and implications of poor sleep from a medical as well as from a social point of view. This EU-financed sleep research project, "The biomedical and sociological effects of sleep restriction", is coordinated by Dr. Tarja Porkka-Heiskanen (Stenberg) MD, PhD, at the University of Helsinki, Institute of Biomedicine.
Doing away with the regulations, which it has deemed are "excessively burdensome," would save an estimated $676 million a year, according to the administration. In other news, The Medicare NewsGroup examines the population of people with a permanent disability who also qualify for Medicare.
GeneTex, a leading manufacturer of antibodies and antibody-related reagents, is set to launch a new antibody against phosphorylated Histone H3.
APP Pharmaceuticals, Inc., a Fresenius Kabi Company, announced today that it will launch both Imipenem and Cilastatin for Injection, USP and Meropenem for Injection, USP in the United States. APP will begin shipping Meropenem for Injection the week of February 13, 2012 with Imipenem and Cilastatin for Injection scheduled to ship in the next three to five weeks.
› Verified 4 days ago